RWA Wealth Partners LLC Has $1.30 Million Position in Aflac Incorporated (NYSE:AFL)

RWA Wealth Partners LLC raised its holdings in Aflac Incorporated (NYSE:AFL - Free Report) by 91.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,581 shares of the financial services provider's stock after buying an additional 6,001 shares during the quarter. RWA Wealth Partners LLC's holdings in Aflac were worth $1,301,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Whipplewood Advisors LLC acquired a new stake in Aflac in the 4th quarter valued at $26,000. BankPlus Trust Department acquired a new stake in shares of Aflac in the 4th quarter valued at $34,000. Curio Wealth LLC bought a new stake in shares of Aflac in the 4th quarter worth about $36,000. Raelipskie Partnership acquired a new stake in shares of Aflac during the 3rd quarter worth about $38,000. Finally, OFI Invest Asset Management bought a new position in Aflac during the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 67.44% of the company's stock.

Aflac Trading Down 8.8 %

Shares of Aflac stock traded down $9.81 during trading on Friday, reaching $101.94. 3,221,784 shares of the company were exchanged, compared to its average volume of 2,138,854. The business has a 50-day moving average price of $106.95 and a 200-day moving average price of $107.70. The firm has a market capitalization of $55.64 billion, a price-to-earnings ratio of 10.62, a P/E/G ratio of 3.24 and a beta of 0.81. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.29. Aflac Incorporated has a twelve month low of $79.31 and a twelve month high of $115.50.

Aflac (NYSE:AFL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The financial services provider reported $1.56 EPS for the quarter, missing analysts' consensus estimates of $1.63 by ($0.07). Aflac had a net margin of 28.76% and a return on equity of 16.20%. Sell-side analysts anticipate that Aflac Incorporated will post 6.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Morgan Stanley lifted their target price on shares of Aflac from $98.00 to $105.00 and gave the company an "equal weight" rating in a research note on Friday, February 28th. StockNews.com raised Aflac from a "sell" rating to a "hold" rating in a research note on Friday, February 14th. Keefe, Bruyette & Woods lowered their target price on Aflac from $107.00 to $104.00 and set a "market perform" rating for the company in a research note on Wednesday, February 12th. JPMorgan Chase & Co. increased their price objective on shares of Aflac from $94.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday. Finally, Piper Sandler raised their price objective on shares of Aflac from $118.00 to $124.00 and gave the company an "overweight" rating in a research report on Wednesday. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $104.29.

Insider Activity at Aflac

In other news, Director Joseph L. Moskowitz sold 1,000 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the sale, the director now owns 25,393 shares of the company's stock, valued at $2,733,048.59. This represents a 3.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Charles D. Lake II sold 29,802 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $107.29, for a total transaction of $3,197,456.58. Following the completion of the transaction, the director now directly owns 49,962 shares of the company's stock, valued at approximately $5,360,422.98. The trade was a 37.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.90% of the stock is owned by corporate insiders.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.